ProNAi Therapeutics (SRRA) Earning Somewhat Positive Media Coverage, Report Finds

Press coverage about ProNAi Therapeutics (NASDAQ:SRRA) has trended somewhat positive on Sunday, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.3247524249432 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Receive News & Ratings for ProNAi Therapeutics Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Shares of ProNAi Therapeutics (NASDAQ:SRRA) traded up 1.33% during trading on Friday, hitting $1.52. 229,482 shares of the company traded hands. ProNAi Therapeutics has a one year low of $1.10 and a one year high of $2.07. The firm has a 50 day moving average price of $1.38 and a 200-day moving average price of $1.36. The stock’s market cap is $79.45 million.

ProNAi Therapeutics (NASDAQ:SRRA) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. Analysts predict that ProNAi Therapeutics will post ($0.91) EPS for the current year.

SRRA has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of ProNAi Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 11th. Jefferies Group LLC reissued a “hold” rating on shares of ProNAi Therapeutics in a research note on Thursday, July 27th.

TRADEMARK VIOLATION WARNING: “[[title]]” was originally posted by [[site]] and is owned by of [[site]]. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at [[permalink]].

About ProNAi Therapeutics

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.